ARTICLE IN PRESS

Journal of Infection xxx (xxxx) xxx–xxx

Contents lists available at ScienceDirect

Journal of Infection

journal homepage: www.elsevier.com/locate/jinf

Corrigendum

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795–813, 5511]

Xinxue Liu [a], Alasdair PS Munro [b,c], Shuo Feng [a], Leila Janani [d], Parvinder K Aley [a,e], Gavin Babbage [b], David Baxter [f], Marcin Bula [g], Katrina Cathie [b,c], Krishna Chatterjee [h], Wanwisa Dejnirattisai [i], Kate Dodd [g], Yvanne Enever [j], Ehsaan Qureshi [k], Anna L. Goodman [l,m], Christopher A Green [k], Linda Harndahl [n], John Haughney [o], Alexander Hicks [n], Agatha A. van der Klaauw [p], Jonathan Kwok [q], Vincenzo Libri [r], Martin J Llewelyn [s], Alastair C McGregor [t], Angela M. Minassian [a,u], Patrick Moore [v], Mehmood Mughal [f], Yama F Mujadidi [e], Kyra Holliday [w], Orod Osanlou [x], Rostam Osanlou [y], Daniel R Owens [b,c], Mihaela Pacurar [b,c], Adrian Palfreeman [z], Daniel Pan [z], Tommy Rampling [r], Karen Regan [aa], Stephen Saich [b], Teona Serafimova [l], Dinesh Saralaya [aa], Gavin R Screaton [i], Sunil Sharma [s], Ray Sheridan [ab], Ann Sturdy [t], Piyada Supasa [i], Emma C Thomson [o,ac], Shirley Todd [ab], Chris Twelves [w], Robert C. Read [b,c], Sue Charlton [ad], Bassam Hallis [ad], Mary Ramsay [ae], Nick Andrews [ae], Teresa Lambe [a], Jonathan S Nguyen-Van-Tam [af], Victoria Cornelius [d], Matthew D Snape [a,e], Saul N Faust [b,c,*], the COV-BOOST study group

[a] *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK*
[b] *NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK*
[c] *Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK*
[d] *Imperial Clinical Trials Unit, Imperial College London, London, UK*
[e] *NIHR Oxford Biomedical Research Centre, Oxford, UK*
[f] *Stockport NHS Foundation Trust, Stockport, UK*
[g] *NIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK*
[h] *NIHR Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK*
[i] *Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK*
[j] *PHARMExcel, Welwyn Garden City, Hertfordshire, UK*
[k] *NIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK*
[l] *Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK*
[m] *MRC Clinical Trials Unit, University College London, London, UK*
[n] *Portsmouth Hospitals University NHS Trust, Portsmouth, UK*
[o] *Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK*
[p] *Wellcome-MRC Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK*
[q] *Cancer Research UK Oxford Centre, University of Oxford, Oxford, UK*
[r] *NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK*
[s] *University Hospitals Sussex NHS Foundation Trust, Brighton, UK*
[t] *Department of Infectious Diseases and Tropical Medicine, London Northwest University Healthcare, London, UK*
[u] *Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK*
[v] *The Adam Practice, Poole, UK*
[w] *NIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK*
[x] *Public Health Wales, Betsi Cadwaladr University Health Board, Bangor University, Bangor, UK*
[y] *University of Liverpool, Liverpool, UK*

DOI of original article: https://doi.org/10.1016/j.jinf.2022.04.018

* Corresponding author at: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

E-mail address: s.faust@soton.ac.uk (S.N. Faust).

https://doi.org/10.1016/j.jinf.2023.03.025

0163-4453/© 2023 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Please cite this article as: X. Liu, A.P. Munro, S. Feng et al., Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795–813, 5511], Journal of Infection, https://doi.org/10.1016/j.jinf.2023.03.025

[z] University Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK
[aa] Bradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK
[ab] Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
[ac] MRC University of Glasgow Centre for Virus Research, Glasgow, UK
[ad] UK Health Security Agency, Porton Down, UK
[ae] UK Health Security Agency, Colindale, London, UK
[af] Division of Epidemiology and Public Health, University of Nottingham School of Medicine, UK

The authors regret that there has been an error published within Fig. 5 of this article. The authors inadvertently pasted the anti-spike plots for the "≥70 years" group instead of the pseudo-neutralising antibody plots (pages 808–809) to Fig. 5A and B. These plots replicate the "≥70 years" group in Fig. 4A and B on pages 806–807. The authors have confirmed that the error does not affect the interpretation of the results and the rest of the paper, and the plots for the "<70 years" group in Fig. 5 are correct. The revised Fig. 5 contains the correct plots for pseudo-neutralising antibody data has now been updated in the original publication. The authors would like to apologise for any inconvenience caused.